Viridian Therapeutics Inc. and Ypsomed AG have signed a supply agreement for Ypsomed's customizable YpsoMate 2.25 autoinjector pen device with a fill volume of 2.0 milliliters. As part of the agreement, Ypsomed will customize and supply YpsoMate2.25 patient-administered delivery devices to support Viridian's development of investigational subcutaneous therapy candidates for the treatment of thyroid eye disease (TED). About Viridian's lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid Eye disease (TED).

In preclinical studies, VRDN-001 was shown to be a full antagonist of IGF-1R, with more complete receptor blockade than other anti-IGF-1R antibodies, including the only currently approved TED therapy. Data from the Phase 2 portion of the ongoing trial established clinical proof-of-concept for VRDN-001 delivered intravenously (IV) in patients with active and chronic TED. VRDN-001 was generally well tolerated in the trial.

The THRIVE Phase 3 trial in patients with active TED is ongoing, and the Company is currently recruiting for its second Phase 3 trial, called THRIVE-2, in patients with chronic TED. The Company is also advancing three candidates (VRDN-001 SC, VRDN-002, and VRDN-003) designed for administration as a convenient, low-volume, subcutaneous (SC) injection for the treatment of TED. Viridian's goal is to bring a best-in-class IV therapy followed by a first- and best-in-class SC therapy to the market for the treatment of the TED.

VRDN-001, -002, and -003 are investigational therapies that are not approved for any use in any country.